LiverRight and Aegle Medical Solutions, LLC have announced a strategic partnership to expand access to non-invasive liver assessment, specialist interpretation, diagnosis, and ongoing liver care for patients across the United States. The collaboration aims to address the significant number of adults living with undiagnosed liver disease by creating a more connected pathway from identification to long-term management.
Aegle Medical provides advanced liver assessment technology, including the Mindray Hepatus-Series Transient Elastography Diagnostic Ultrasound Systems, along with implementation, clinical training, and ongoing customer support. LiverRight is a national virtual liver clinic offering specialist interpretation and access to hepatology clinicians. Together, they aim to help healthcare organizations move patients efficiently from liver disease identification to specialist interpretation and longitudinal management.
For physicians, health systems, and independent practices, the partnership is designed to make it easier to establish or expand comprehensive liver disease programs without building every component internally. Aegle Medical offers a consultative approach to technology evaluation, implementation, and training, while LiverRight provides same-day interpretation services for liver elastography studies and same-week virtual access to its hepatology clinicians. LiverRight's Liververse™ referral system coordinates bloodwork, patient-reported outcomes, imaging, diagnosis, and longitudinal disease management.
For patients, the combined model is intended to bring advanced liver assessment closer to the communities where they already receive care and improve access to liver specialists. The goal is to create a more efficient pathway from identifying at-risk patients to non-invasive assessment, specialist review, diagnosis, and appropriate ongoing care.
Brandon Tudor, CEO of LiverRight, stated, "Aegle Medical Solutions is helping hospital systems and independent practices nationwide address the significant number of adults living with undiagnosed liver disease in the United States. By working together, we help practices bring advanced liver assessment into the outpatient setting, provide timely specialist interpretation, and move patients into the appropriate diagnostic and care workflow with greater efficiency."
Michael McTighe, President & CEO of Aegle Medical Solutions, added, "This strategic partnership with LiverRight represents an important step forward in our shared vision of expanding access to liver disease detection and care within the communities we serve. By connecting those capabilities with LiverRight's nationwide virtual liver-care network and same-day interpretation services, we can provide our customers with more than technology—we can help them establish a more complete pathway from assessment to diagnosis and ongoing patient management."
The partnership also highlights the Mindray Hepatus platform, which introduces Visualized Transient Elastography (ViTE), integrating real-time B-mode ultrasound visualization into elastography examinations. This allows operators to see liver anatomy, identify optimal measurement locations, and guide each acquisition while obtaining quantitative liver stiffness and attenuation measurements. The Hepatus platform provides liver stiffness measurement for fibrosis assessment and Liver UltraSound Attenuation for hepatic steatosis assessment. The Hepatus 6 further expands capabilities with diagnostic ultrasound imaging, including abdominal imaging, Doppler, spleen stiffness assessment, and intestinal ultrasound.
LiverRight has its own hepatologists and advanced practice providers licensed in all 50 states, supporting adults with conditions such as MASLD/MASH, alcohol-associated liver disease, hepatitis B and C, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, and liver cancer. The partnership offers a scalable approach for health systems, GI and hepatology practices, and independent providers to expand liver services under their own brand.
This collaboration could significantly impact public health by enabling earlier detection and treatment of liver disease, potentially reducing complications and improving outcomes for millions of Americans. For healthcare providers, it offers a streamlined pathway to offer comprehensive liver care without extensive internal infrastructure, which may lead to better resource utilization and patient satisfaction.
